Phase I Study of OPC-61815

NCT03510663 PHASE1 COMPLETED Results posted

To investigate the effects of intravenous administration of OPC-61815 at 16 and 32 mg on QT/QTc interval in healthy male subjects

Details

Lead sponsor	Otsuka Pharmaceutical Co., Ltd.
Phase	PHASE1
Status	COMPLETED
Enrolment	48
Start date	Tue May 08 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jul 05 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Congestive Heart Failure

Interventions

• OPC-61815 16mg
• OPC-61815 32mg
• Moxifloxacin
• Placebos

Countries

Japan